3.98
-0.0891(-2.19%)
Currency In USD
| Previous Close | 4.07 |
| Open | 4.04 |
| Day High | 4.08 |
| Day Low | 3.96 |
| 52-Week High | 29.3 |
| 52-Week Low | 3.81 |
| Volume | 765,529 |
| Average Volume | 1.91M |
| Market Cap | 366.95M |
| PE | -3.55 |
| EPS | -1.12 |
| Moving Average 50 Days | 7.52 |
| Moving Average 200 Days | 16.19 |
| Change | -0.09 |
If you invested $1000 in Myriad Genetics, Inc. (MYGN) 10 years ago, it would be worth $115.05 as of May 22, 2025 at a share price of $3.981. Whereas If you bought $1000 worth of Myriad Genetics, Inc. (MYGN) shares 5 years ago, it would be worth $270.26 as of May 22, 2025 at a share price of $3.981.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
GlobeNewswire Inc.
May 14, 2025 8:45 PM GMT
Correction: Time of BofA ConferenceSALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to participate in the f
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
GlobeNewswire Inc.
May 07, 2025 8:30 PM GMT
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual riskSALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicin
Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor
GlobeNewswire Inc.
Apr 30, 2025 12:00 PM GMT
More than half say genetic testing for mental health medications could reduce concernsSALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medicatio